Leukemia News

Oncology clinical trials appeared to recover from declines in enrollment and activation during the early phase of the COVID-19 pandemic, according to a study of data from two large academic centers published in Annals of Oncology.

Researchers have developed a genetically modified form of the immune-stimulating protein interleukin-7 that significantly enhanced chimeric antigen receptor T-cell therapy activity in preclinical testing.

Less than half of patients with hematologic malignances exhibited seroconversion after receiving their initial COVID-19 vaccine, research published in Cancer showed.

Koen van Besien, MD, PhD, has been appointed chief of the division of hematology at University Hospitals Seidman Cancer Center.

Nearly 40% of patients who received chimeric antigen receptor T-cell therapy required hospitalization for disease- or treatment-related reasons in the year after infusion, results of a research letter in JAMA Oncology showed.

The use of broad-spectrum antibiotics in the month leading up to chimeric antigen receptor T-cell therapy led to poorer outcomes and increased treatment-related toxicities, study results showed.

Childhood leukemia survival outcomes in patients with musculoskeletal involvement are similar to those among patients without musculoskeletal disease, according to data published in Pediatric Rheumatology.

Marco Davila, MD, PhD, has been appointed senior vice president and associate director for translational research at Roswell Park Comprehensive Cancer Center.

The FDA issued a warning about a potentially increased risk for death or serious adverse effects with duvelisib, an approved blood cancer therapy.

Black and Hispanic patients with acute myeloid leukemia who resided in socially disadvantaged neighborhoods had a significantly greater risk for mortality than their white counterparts, according to study results published in Blood.